Combination Immunotherapy with Ipilimumab and Nivolumab plus a Dendritic Cell based p53 Vaccine (Ad.p53 -DC) in patients with relapsed Small Cell Lung Cancer (SCLC) NCT0 3406715 Version 8 September 19, 2018 Protocol: Version 8.0. September 19, 2018 Page | 1 SPONSOR: Moffitt Cancer Center Protocol Title: Combination Immunotherapy with Ipilimumab and Nivolumab plus a Dendritic Cell based p53 Vaccine (Ad.p53- DC) in patients with relapsed Small Cell Lung Cancer (SCLC) BMS Protocol Number: CA209- 9KN Moffitt Protocol Number: MCC 19163 MultiVir Protocol Number: MVIR -Adp53DC -001 Principal Investigator: Alberto Chiappori, MD Senior Member Thoracic Oncology Department Moffitt Cancer Center 12902 Magnolia Drive Tampa, FL 33612 Phone: 813-745-3050 Fax: 813-745-3027 Email: alberto.chiappori@moffitt.org Version/Date: 8/ September 19, 2018 Amendment/date: 7/September 19, 201 8 Protocol: Version 8.0. September 19, 2018 Page | 2 TABLE OF CONTENTS – INDEX 1.0 TRIAL SUMMARY .....................................................................................................